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SUMMARY
 Chemical composition, antimicrobial and cytotoxic activities 
of commercial essential oils’ samples from the aerial plant parts of H. 
officinalis, R. officinalis and S. officinalis were investigated. Analyses by 
GC-FID and GC-MS confirmed 52 oil components. The major constituent 
of the H. officinalis oil was cis-pinocamphone (34.4%), followed by trans-
pinocamphone (23.3%), and β-pinene (11.3%). Analysis of R. officinalis 
oil revealed 1.8-cineol as a major constituent (43.8%), as well as trans-
pinocamphone (12.5%), α-pinene (11.5%) and β-pinene (8.2%). The 
most dominant constituent of S. officinalis oil was cis-thujone (32.7%), in 
addition to camphor (17.2%), 1.8-cineol (10.1%), α-pinene (8.6%), trans-
thujone (7.7%) and camphene (7.3%). The essential oil antimicrobial 
activity assay was performed by the use of microdilution method against 
oral Candida spp. and bacteria, the major causative agents of a number of 
human oral disorders; all of them were susceptible to tested concentrations 
of H. officinalis, R. officinalis and S. officinalis essential oils, although the 
oil of S. officinalis exhibited the lowest antimicrobial potential. The results 
obtained in this study encourage use of investigated essential oils from 
Lamiaceae family in development of safe natural agents for prevention and/
or alternative therapy of human oral diseases. However, a special care 
during development of an effective natural preparation is required.
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Introduction
Worldwide, we are witnessing a strong promotion 
on the reduction in use of synthetic products1. The 
emergence of resistance to broad-spectrum antibiotics, the 
appearance	of	hypersensitivity	 to	 the	drugs,	 toxicity	 as	 a	
result	 of	 improper	 and	 excessive	 application,	 represent	
just some of the consequences of the use of synthetic 
antimicrobial agents.
Recently, many scientists began to understand 
the importance of traditional medicine; data regarding 
application of medicinal plants can be searched in 
historical manuscripts but have to be verified by a modern 
science in order to develop an effective drug2. Taking into 
account that plants produce hundreds or even thousands 
of metabolites, it is obvious that there is a great interest 
in their chemical evaluation3. In recent decades, scientists 
have carried out an intensive biological and chemical 
examination	 of	 the	 plant	 secondary	 metabolites4, 5, 
particularly essential oils. In oral medicine, essential oils 
are used in many different ways, such as: in oral hygiene, 
in	dental	implants,	as	anxiolytic	and	preservatives6.
Oral cavity has over 700 different types of 
microorganisms of which, currently, more than a half 
is not possible to cultivate in the laboratory conditions. 
Around 400 species derive from periodontal pockets, 
while about 300 species are isolated from the mucous 
membrane, carious lesions, tongue and other human 
oral cavity surfaces7. The most common oral infection, 
with a growing trend in the last decades, is candidiasis, 
whose main causative agent is opportunistic pathogen 
Candida albicans. Although it is a part of normal 
10.1515/bjdm-2016-0026
Melaleuca alternifolia (organic) from Bergland-Pharma 
GmbH and Co. KG.
Essential oil analysis
Procedure used for GC-FID and GC-MS analyses 
complies with standards set for Gas Chromatography of 
essential oils.
GC-FID analysis was performed on GC Agilent 
Technologies	 7890A	 apparatus,	 equipped	 with	 the	 split-
splitless injector and automatic liquid sampler (ALS), 
attached	to	HP-5	column	(30	m	x	0.32	mm,	film	thickness	
0.25 µm) and fitted to flame-ionization detector (FID). 
Operating conditions were as follows: carrier gas was H2 
(1 ml/min/210°C); temperatures of injector and detector 
were set at 250°C and 280°C, respectively, while the 
column temperature was linearly programmed 40–260°C 
at 4°C/min. Solutions of essential oils’ samples in ethanol 
(ca. 1%) were consecutively injected by ALS (1 µl, split-
mode). The percentile presence of components in essential 
oils’ samples were calculated from the peak areas obtained 
in the area-percent reports (obtained as a result of standard 
processing of chromatograms) without correction factors, 
using normalization method.
The GC/MS was performed on HP G 1800C Series 
II GCD analytical system equipped with HP-5MS column 
(30 m×0.25 mm, film thickness 0.25 µm). Carrier gas was 
He (1 ml/min). Other chromatographic conditions were 
as those for GC-FID. Transfer line was heated at 260°C. 
Mass spectra were recorded in EI mode (70 eV), in a 
range of m/z 40–450. Solutions of essential oil samples in 
ethanol (ca. 1%) were consecutively injected by ALS (0.2 
µl, split mode).
The identification of essential oils components 
was based on matching of their mass spectra peaks 
with those from Wiley275 and NIST/NBS libraries. 
The	 experimental	 values	 for	 Kovats’	 retention	 indices	
(RI) were determined by using calibrated Automated 
Mass Spectral Deconvolution and Identification System 
software AMDIS (ver. 2.1.), compared to those from 
available literature15, and they were used as additional 
tool to support MS findings.
Microorganisms
The following seven clinical oral isolates: 
Streptococcus pyogenes (IBR S004), Streptococcus 
mutans (IBR S001), Lactobacillus acidophilus 
(IBR L001), Streptococcus salivarius (IBR S006), 
Streptococcus sangunis (IBR S002), Streptococcus 
sanguis (IBR S005), Enterecoccus feacalis (IBR E001), 
Pseudomonas aeruginosa (IBR P001) and one reference 
strain, Staphylococcus aureus	 (ATCC	 25923),	 were	
used in the study. In antifungal assay, fifty eight clinical 
isolates of Candida spp., as well as two references 
strains (Candida albicans ATCC 10231 and Candida 
tropicalis ATCC 750), were used. The reference strains 
were obtained from the collection of the Laboratory 
microbiota, after the homeostatic conditions in oral cavity 
changes, it starts overgrowing and causing very specific 
symptoms8. The most common reasons for the infection 
use	to	be	the	excessive	use	of	broad-spectrum	antibiotics,	
immunosuppressant’s (corticosteroids and cytostatics), 
inadequate dentures an poor oral hygiene9. During the 
mid-twentieth and early twenty-first century, a rise in 
the number of species of the genus Candida infections, 
especially in immunocompromised patients (HIV, 
diabetes, cancer) was recorded10. This provoked a great 
interest	 in	 studying	 existing	 therapeutic	 procedures	 and	
causes of infections that may range from mucosal lesions 
to the life-threatening systemic infections. 
In addition to Candida spp., species of the genera 
Staphylococcus, Enterobacter and Pseudomonas are 
also a common cause of pathogenic conditions in the 
human oral cavity11. While the C. albicans was detected 
in	 55.5%,	 61.1%	and	 61.1%	 samples	 from	 the	maxillary	
defect area, prosthesis and saliva, respectively, S. aureus 
was detected in 44.4% of the nasal cavity samples, and 
all samples of saliva from the same patients were positive 
for	 this	 pathogen,	 except	 one.	None	of	 the	 patients	were	
suffering from any subjective complains, while 50% of 
them had diffuse erythema in the defect area. Both C. 
albicans and S. aureus were detected together in 22.2% 
of all saliva samples12. Patients with symptoms of denture 
related stomatitis (DRS) and poor denture hygiene had in 
their saliva a pronounced number of C. albicans13.
Caries is a chronic disease of the tooth hard tissues, 
leading to demineralization and decay. Some studies 
indicate the important role of some Streptococcus bacteria 
strains in etiology of this disease14, among which the most 
common belong to Streptococcus mutans group, and the 
other ones were species S. sobrinus, S. salivarius, S. mitis, 
S. constellatus, S. parasanguinis, Lactobacillus spp. and 
Vellionella spp. Actinomyces species are involved in the 
initial stages of caries, while the S. mutans in the later ones7.
The enormous structural diversity of natural 
compounds of plant origin provides opportunity to obtain 
effective antimicrobial agents. Since biological activities 
of	essential	oils	have	been	extensively	studied,	and	some	
of them were scientifically confirmed, they represent an 
ideal model for study and use in prevention and treatment 
of the human oral diseases caused by the most common 
pathogens.
Material and methods
Essential oils 
Three EOs were used in this study, all of them were 
purchased as commercial samples; Citrus limon L. oil 
from “Scents & Sensibility ltd.”, USA, Piper nigrum 
L. oil from “Athens Herbal Pharmacy”, Greece, and 
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In the oil of R. officinalis, 1.8-cineol was the major 
constituent (43.8%), followed by trans-pinocamphone 
(12.5%), α-pinene (11.5%), and β-pinene (8.2%). The 
most abundant constituents of S. officinalis EO were cis-
thujone (32.7%), camphor (17.2%), 1.8-cineol (10.1%), 
α-pinene (8.6%), trans-thujone (7.7%), and camphene 
(7.3%). The chemical profile of our commercial EO 
sample of H. officinalis is in agreement with previous 
studies21, 22, though there is another study of the oil of 
H. officinalis revealing β-pinene and camphor being the 
major oil components, in addition to pinocamphone23. 
Antimicrobial activity
In	 general,	 all	 EOs	 exhibited	 significant	
antimicrobial activity against tested microorganisms 
(Table 2 and Table 3); inhibition values ranged for MIC 
0.16-1.25 mg/ml and MBC 0.63-2.50 mg/ml for bacteria, 
and MIC 0.13-63 mg/ml and MFC 0.50-1.25 mg/ml for 
Candida spp. 
The strongest activity against bacteria was achieved 
by H. officinalis and R. officinalis oils (MIC 0.16-0.63 
mg/ml and MBC 0.31-1.25 mg/ml), while S. officinalis 
EO showed weaker antibacterial potential (MIC 0.63-1.25 
mg/ml and MBC 1.25-2.50 mg/ml). The positive control 
used in this study, streptomycin, inhibited the growth of 
selected bacteria in the range MIC 0.01-0.15 mg/ml and 
MBC 0.01-0.20 mg/ml. Even Streptomycin showed better 
results in comparison to EOs, this result should be taken 
with caution; direct comparison of Streptomycin with 
EOs is better to avoid, since Streptomycin is commercial 
antibiotic	 and	 EOs	 are	 mixtures	 of	 natural	 compounds.	
On the other hand, commercial preparation Curasept 
(MIC 0.50-10.00, MBC 1.00-20.00 mg/ml) showed 
lower antibacterial potential compared to our EOs, with 
exception	 of	 S. sanguinis, while antibacterial potential 
of	Hexoral	 (MIC	0.19-1.56,	MBC	0.39-3.12	mg/ml)	was	
lower in comparison to H. officinalis and R. officinalis 
oils, though it was similar to even better compared to S. 
officinalis EO (Table 2). 
The results of antifungal activity of commercial H. 
officinalis EO (MIC 0.13-0.50, MFC 0.25-1.00 mg/ml) 
and R. officinalis EO (MIC 0.25-0.50, MFC 0.50-1.00 mg/
ml) showed the strongest biocidal effect with the lowest 
MIC and MFC values, while the oil from S. officinalis 
again showed lowest potential among the tested oils (MIC 
0.31-0.63, MFC 0.63-1.25 mg/ml). In comparison to 
Fluconazole (MIC 0.0005-0.002; MFC 0.001-0.004 mg/ml) 
the EOs in our study generally showed lower activity (Table 
3). Positive control Curasept showed the lowest antifungal 
potential with MIC range from 5.00 to 10.00 mg/ml and 
MFC	from	10.00	 to	20.00	mg/ml,	while	Hexoral,	 as	well,	
had weaker influence on tested fungi compared to EOs 
(MIC 1.00-1.25, MFC 2.00-2.50 mg/ml).
Recent study showed moderate antibacterial effect 
of H. officinalis essential oil 24. Similar results were 
of Mycology at the Institute for Biological Research 
‘’Siniša	Stanković’’,	University	 of	Belgrade,	 Serbia.	The	
bacteria species were maintained in Mueller Hinton Agar 
and Tryptic Soy Agar (MHA, TSA, Merck Germany). 
Strains of Candida spp. were maintained on Sabourand 
Dextrose	 Agar	 (SDA,	 Merck,	 Germany).	 All	 clinical	
oral isolates were obtained by rubbing a sterile cotton 
swab over oral mucosa from patients at the Department 
of Pediatric and Preventive Dentistry, Faculty of Dental 
Medicine, University of Belgrade, Serbia. The colonies 
obtained were analysed for morphological, cultural and 
physiological characteristics. Proper identification of oral 
bacteria 16 and fungi 17 colonies were performed.
Antimicrobial activity
Minimum inhibitory (MIC) and minimum 
bactericidal/fungicidal (MBC/MFC) concentrations 
were	 determined	 by	 microdilution	 method	 in	 96	 well	
microtitre plates18,	 19 with some modifications. Briefly, 
fresh overnight cultures of bacteria were adjusted with 
sterile	saline	to	a	concentration	of	1.0	x	105 CFU/well for 
bacteria and fungi, respectively. EOs were added in TSB 
medium for bacteria, SDB medium for C. albicans. The 
microplates were incubated for 24 h at 37° C for bacteria 
and 48 h at 37° C for yeasts. The  MIC  was  defined  as 
the  lowest concentration  of  EO  inhibiting  the  visible 
growth  of  the  test  strain. The MIC/MBC values for 
bacteria and yeasts were detected following the addition 
of	40	μL	of	p-iodonitrotetrazolium	violet	(INT)	0.2	µg/ml	
(Sigma I8377) and incubation at 37 °C for 30 min20. The 
MBCs/MFCs were determined by serial sub-cultivation 
of 10 µL into microtiter plates containing 100 µL of broth 
per well and further incubation for 24 h at 37° C. The 
lowest concentration with no visible growth was defined 
as	 the	 MFC,	 indicating	 99.5	 %	 killing	 of	 the	 original	
inoculum.	 Positive	 controls,	 antibiotics	 (Hexoral®,	
Streptomycin) and mycotic (Fluconazole), were used in 
both	experiments.
Results and Discussion
Chemical composition of essential oils
Results of chemical analysis of essential oils (EO) 
used	in	this	experiment	is	presented	in	Table	1.	It	resulted	
in	 identification	 of	 52	 components	 representing	 99.9-
100.00% of the oils. 
Oxygenated	 monoterpenes	 are	 the	 major	 portion	
of our EO samples, with the highest content observed in 
S officinalis (72.0%), somewhat lower in H. officinalis 
oil	 (65.9%)	 and	 the	 lowest	 in	R. officinalis oil	 (63.9%).	
Twenty five compounds were identified in H. officinalis 
oil,	 accounting	 for	 99.9%	 of	 the	 total	 EO;	 the	 major	
constituent was cis-pinocamphone (34.4%), followed 
by trans-pinocamphone (23.3%), and β-pinene (11.3%). 
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in other study26, which concentration of 104 mg/ml was 
needed in order to inhibit growth of Aspergulus niger. 
Great variability in antifungal activity of H. officinalis 
EO	samples	of	various	origins	 can	be	 explained	by	 their	
different chemical composition, testing methods and 
microbial	strains	used	in	experiments.	
also documented by other researchers who investigated 
the effect of this oil on the Gram-negative bacteria, P. 
aeruginosa, E. coli and S. typhimurium 25. In this study, 
H. officinalis EO had a moderate effect on seven strains 
of C. albicans, C. krusei, and C. tropicalis, inhibiting their 
growth in concentrations of 0.6-1.2% (v / v). However, 
variable antifungal potential of this EO was also observed 
Table 1. Chemical composition of H. officinalis, R. officinalis and S. officinalis essential oils’ commercial samples used in experiment
Components RI
Essential oils
H. officinalis R.officinalis S.officinalis
cis-Salvene 861 - - 0.6
trans-Salvene 868 - - 0.1
Tricyclene 917 - 0.2 0.2
α-Thujene 923 0.6 0.1 -
α-Pinene 927 1.2 11.5 8.6
Camphene 942 - 4.6 7.3
Sabinene 968 - 0.1 -
β-Pinene 969 11.3 8.2 1.2
Myrcene 985 0.8 1.0 0.8
α-Phellandrene 1001 - 0.2 -
δ-3Carene	 1005 - 0.1 -
α-Terpinene 1013 - 0.1 0.2
para-Cimene 1019 0.3 1.2 1.1
Limonene 1023 - 2.8 2.1
β-Phellandrene 1023 2.6 - -
1.8-Cineol 1025 0.7 43.8 10.1
γ-Terpinene	 1053 - 0.9 0.4
α-Terpinolene 1086 - 0.2 0.3
Linalool 1097 1.3 0.5 -
cis-Thujone 1103 - - 32.7
trans-Thujone 1115 - - 7.7
trans-Pinocarveol 1131 2.2 - -
Camphor 1140 - 12.5 17.2
Isoborneol 1155 - 0.5 -
trans-Pinocamphone 1156 23.3 - -
3-Thujanol 1165 - - 0.1
Borneol 1165 - 3.0 2.4
cis-Pinocamphone 1167 34.4 - -
Terpinene-4-ol 1176 - 0.6 0.4
α-Terpineol 1187 - 1.5 -
Myrtenol 1190 1.4 - -
γ-Terpineol 1196 - 0.4 -
trans-2-Pinocamphonehydroxy 1242 0.5 - -
Linalyl acetate 1249 1.6 - -
Bornyl acetate 1285 - 1.1 1.2
trans-Sabinyl acetate 1290 - - 0.1
Myrtenyl acetate 1318 0.5 - -
α-Copaene 1371 - 0.1 -
β-Bourbonene	 1386 3.5 - -
Longifolene 1399 - 0.2 -
α-Gurjunene 1408 0.5 - -
(E)Caryophyllene 1412 2.7 3.9 0.9
β-Copaene 1431 0.4 - -
α-Humulene 1446 0.5 0.4 3.5
Alloaromadendrene 1451 2.2 - -
Germacrene D 1480 3.1 0.1 -
Bicyclogermacrene 1498 2.7 - -
γ-Cadinene 1504 - - 0.1
δ-Cadinene	 1516 - 0.1 -
Elemol 1540 1.1 - -
Spathulenol 1572 0.8 - -
Globulol 1583 - - 0.6
Monoterpene hydrocarbons 16.7 31.2 22.9
Oxigenated monoterpenes 65.9 63.9 72.0
Sesquiterpene hydrocarbons 15.5 4.8 4.6
Oxigenated sesquiterpenes 1.8 - 0.6
Total identified  99.9 99.9 100.0
Total number of components 25 29 25
RI-retention	index	
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Table 2. Antibacterial activity of essential oils from H. officinalis, R. officinalis, and S. officinalis (mg/ml)
# Bacteria
H. officinalis R. officinalis S.officinalis Curasept® Hexoral® Streptomicin
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
1 S. a 0.16 0.31 0.16 0.31 0.63 1.25 2.50 5.00 1.56 3.12 0.08 0.16
2 S. p 0.31 0.63 0.31 0.63 0.63 1.25 2.00 4.00 0.65 1.31 0.04 0.08
3 S. m 0.31 0.63 0.31 0.63 1.25 2.50 0.50 1.00 1.56 3.12 0.02 0.04
4 L. a 0.31 0.63 0.31 0.63 1.25 2.50 4.50 9.50 1.56 3.12 0.04 0.08
5 S. sl 0.16 0.31 0.16 0.31 0.63 1.25 2.00 4.00 0.78 1.56 0.01 0.02
6 S. sn 0.16 0.31 0.16 0.31 0.63 1.25 0.50 1.00 0.19 0.39 0.02 0.04
7 P. a 0.63 1.25 0.63 1.25 1.25 2.50 10.00 20.00 0.78 1.56 0.15 0.20
8 E. f 0.31 0.63 0.16 0.31 0.63 1.25 5.00 10.00 0.78 1.56 0.01 0.01
S.a – Staphylococcus aureus, S. p – Streptococcus pyogenes, S. m – Streptococcus mutans, L. a – Lactobacillus acidophilus, 
S. sl – Streptococcus salivarius, S. sn – Streptococcus sanguinis, P. a – Pseudomonas aeruginosa, E. f – Enterococcus feacalis
Table 3. Antifungal activity of essential oils from H. officinalis, R. officinalis, and S. officinalis (mg/ml).
# Fungi
H. officinalis R. officinalis S. officinalis Curasept® Hexoral® Flukonazol
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
1 C.a. 1/1617 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
2 C.a. MH2 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
3 C.a. MH1 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.001 0.002
4 C.a. 4/30 0.50 1.00 0.25 0.50 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
5 C.a. 4/23 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
6 C.a. 2/7.4 0.25 0.50 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
7 C.a. 1/315 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 1.50 0.002 0.004
8 C.a.2/16 0.50 1.00 0.50 1.00 0.63 1.25 5.00 10.00 1.00 2.00 0.0005 0.001
9 C.a. 2/20 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
10 C.a. 2d 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
11 C.a. 4/2.2 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
12 C.a. 7d 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
13 C.a. 1/27 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.25 2.50 0.001 0.002
14 C.a. Lj2 0.50 1.00 0.50 1.00 0.63 1.25 12.50 25.00 1.00 2.00 0.0005 0.001
15 C.a. 2/8.12 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.001 0.002
16 C.a. 1/0407 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
17 C.a. 4/30 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
18 C.a. 2/23 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.25 2.50 0.0005 0.001
19 C.a. 2/24 0.50 1.00 0.50 1.00 0.63 1.25 12.50 25.00 1.00 2.00 0.002 0.004
20 C.a. 5/30 0.25 0.50 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
21 C.a. Danc 0.50 1.00 0.25 0.50 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
22 C.a. 2/7.5 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.001 0.002
23 C.a. 10d 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
24 C.a. 1/31.7 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
25 C.a .5/7.4 0.50 1.00 0.50 1.00 0.63 1.25 5.00 10.00 1.00 2.00 0.002 0.004
26 C.a. 2/3.11 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.25 2.50 0.001 0.002
27 C.a. 2/212 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
28 C.a. 2/31.5 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
29 C.a. 3/16 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
30 C.a. 5/7.4 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
31 C.a.	1flak2 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
Balk J Dent Med, Vol 20, 2016 Antimicrobial Activity Of Essential Oils  165
# Fungi
H. officinalis R. officinalis S. officinalis Curasept® Hexoral® Flukonazol
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
32 C.a. 4/3.12 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
33 C.a.	3flak1 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
34 C.a. 5/1617 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
35 C.a. 4/07 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
36 C.a. 4/23.11 0.50 1.00 0.50 1.00 0.63 1.25 12.50 25.00 1.00 2.00 0.001 0.002
37 C.a. 3/31.5 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
38 C.a. 1d 0.25 0.50 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
39 C.a. 1/16 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
40 C.a. d11 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
41 C.a. 4/16 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
42 C.a. MH4 0.50 1.00 0.50 1.00 0.63 1.25 12.50 25.00 1.00 2.00 0.002 0.004
43 C.a. 8/12.11 0.50 1.00 0.50 1.00 0.63 1.25 12.50 25.00 1.00 2.00 0.0005 0.001
44 C.a. 1/12.5 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
45 C.a. cet1 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.001 0.002
46 C.a. 2/7.12 0.50 1.00 0.25 0.50 0.63 1.25 10.00 20.00 1.25 2.50 0.0005 0.001
47 C.a. cet5 0.13 0.25 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
48 C.a. 1/20 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
49 C.a. 3/13 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
50 C.a. 2/21 0.50 1.00 0.50 1.00 0.63 1.25 5.00 10.00 1.00 2.00 0.0005 0.001
51 C.a. 5/32 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.002 0.004
52 C.a. 4/20.12 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
53 C.a. 3/11 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.25 2.50 0.0005 0.001
54 C.a. 7/16 0.50 1.00 0.25 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.001 0.002
55 C.a. 5d 0.50 1.00 0.50 1.00 0.63 1.25 5.00 10.00 1.00 2.00 0.0005 0.001
56 C.	k.	1flak1 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 - -
57 C. g. 2/06 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0015 0.003
58 C. g. 6/23 0.50 1.00 0.50 1.00 0.63 1.25 10.00 20.00 1.00 2.00 0.0015 0.003
59 ATCC 10231 0.25 0.50 0.25 0.50 0.63 1.25 10.00 20.00 1.00 2.00 0.0005 0.001
60 ATCC 750 0.25 0.50 0.25 0.50 0.31 0.63 5.00 10.00 1.00 2.00 0.002 0.004
* C.a. – Candida albicans; C.k. – Candida krusei; C.g. – Candida glabrata;  
ATCC (The American Type Culture Collection) 10231 – Candida albicans; ATCC 750 – Candida tropicalis.
Several articles report bactericidal effect of essential 
oil of R. officinalis27, 28. The oil is presented as very 
active in inhibiting the growth of S. aureus, E. coli, S. 
typhimurium and L. monocytogenes due to its abundance 
in	monoterpenes	 (1,8-cineol,	 α-	 and	 β-pinene,	 camphor),	
which contribute to the EO’s overall antibacterial 
activity29. Earlier studies on antifungal activity of this 
oil reported different results in comparison to ours; one 
study30 showed moderate activity of oil to C. albicans and 
C. krusei (inhibiting their growth in concentrations of 0.5 
and 1 mg/ml, respectively), while in other investigations28 
the oils from the same species originating from different 
localities in Turkey, also showed moderate to weak 
activity on C. albicans. 
According to data from the literature31-33, 
antibacterial potential of S. officinalis EO, tested in 
vitro study, is very low; the lipophilic nature of some 
constituents of the essential oils from Salvia species 
resulted in a weak in vitro antibacterial activity as opposed 
to in vivo tests which showed very good activity32. In 
one study scientist compared the ability of C. albicans 
to	adhere	 to	 two	permanent	 soft	 liners	and	examined	 the	
effectiveness	 of	 alkaline	 peroxide-type	 denture	 cleansers	
in disinfection of contaminated long-term soft lining 
materials34.	 Since	 the	mentioned	 cleaners	 could	 be	 toxic	
and destructive, here we could suggest the testing of 
natural products as an alternative. 
Conclusion
In conclusion, present study shows that H. officinalis, 
R. officinalis, and S. officinalis essential oils possess 
broad-spectrum antimicrobial activity toward the oral 
microorganisms involved in various oral infections and 
diseases. The results of this study encourage the use of 
tested EOs in development of a novel agent that can be 
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Patients Wearing Upper Full Removable Dentures. Balk J 
Stom, 2008; 12:98–102.
14. Nicolas GG, Lavoie MC. Streptococcus mutans and oral 
streptococci in dental plaque. Can J Microbiol, 2011; 57:1–20. 
15. Adams RP. Identification of Essential Oil Compounds by Gas 
Chromatography and Mass Spectrometry (fourth ed.),” Allured 
Publishing	Corporation:	Carol	Stream,	2009;	IL,	USA.
16. Cecchini C, Silvi S, Cresci A, Piciotti A, Caprioli G, Papa 
F, Sagratini G, Vittori S, Maggi F. Antimicrobial efficacy 
of Achillea ligustica All. (Asteraceae) essential oils 
against reference and isolated oral microorganisms. Chem 
Biodivers,	2012;	9:12–24.	
17. Nikolić	M,	Glamočlija	J,	Ćirić	Ana	P,	Tamara	M,	Dejan	S,	
Tanja SM, Antimicrobial activity of ozone gas and colloidal 
silver against oral microorganisms. Dig J Nanomater, 2012; 
7:1693–1699.
18. Douk KD, Dagher MS, Sattout JE. Antifungal activity of the 
essential oil of Origanum syriacum L. J Food Protect,	1995;	
58:1147–1149.
19.	 European Committee on Antibiotic Susceptibility 
EUCAST Method for determination of minimal inhibitory 
concentration (MIC) by broth dilution of fermentative 
yeasts. Discussion document E. Dis. 7.1. European Society 
of Clinical Microbiology and Infectious Diseases, 2002; 
Taufkirchen, Germany.
20. Tsukatani T, Suenaga H, Shiga M, Noguchi K, Ishiyama 
M, Ezoe T, Matsumoto K. Comparison of the WST-8 
colorimetric method and the CLSI broth microdilution 
method for susceptibility testing against drug-resistant 
bacteria. J Microbiol Methods,	2012;	90:160–166.	
21. Glamočlija	J,	Soković	M,	Vukojević	J,	Milenković	I,	Brkić	
D, Van G. Antifungal activity of essential oil Hyssopus 
officinalis L. against micopathogen Mycogone perniciosa 
(Mang). Zb Matice Srp za Prir Nauk, 2005; 188.
22. Fathiazad F. A review on Hyssopus officinalis L.: 
Composition and biological activities. African J Microbiol 
Res,	2011;	5:1959–1966.	
23. Salma AS. Chemical and physiological studies on anise 
hysop (Agastache foeniculum Pursh) and hyssop (Hyssopus 
officinalis L) plants grown in Egypt as new spices. Bulletin 
of the National Research Centre, 2002; 27:25–35.
24. Nedorostova L, Kloucek P, Kokoska L, Stolcova M, 
Pulkrabek J. Antimicrobial properties of selected essential 
oils in vapour phase against foodborne bacteria. Food 
Control,	2009;	20:157–160.	
25. Mazzanti G, Battinelli L, Salvatore G. Antimicrobial 
properties of the linalol-rich essential oil of Hyssopus 
officinalis L. vardecumbens (Lamiaceae). Flavour Fragr J, 
1998;	13:289–294.	
26. Džamić	 AM,	 Soković	 MD,	 Novaković	 M,	 Jadranin	 M,	
Ristić	MS,	 Tešević	 V,	Marin	 PD.	 Composition,	 antifungal	
and	antioxidant	properties	of	Hyssopus officinalis L. subsp. 
pilifer	 (Pant.)	Murb.	 essential	 oil	 and	 deodorized	 extracts.	
Ind Crops Prod, 2013; 51:401–407. 
27. Weckesser S, Engel K, Simon-Haarhaus B, Wittmer A, 
Pelz	 K,	 Schempp	 CM.	 Screening	 of	 plant	 extracts	 for	
antimicrobial activity against bacteria and yeasts with 
dermatological relevance. Phytomedicine, 2007; 14:508–516. 
used in prevention and therapeutic treatments of human 
oral diseases. However, further in-depth study regarding 
the efficacy and safety should be conducted, followed by 
a number of clinical trials before the final product find its 
place at pharmacy shelves.
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